<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590197</url>
  </required_header>
  <id_info>
    <org_study_id>IEC/AIIMSBBSR/PGTh/18-19/02</org_study_id>
    <nct_id>NCT03590197</nct_id>
  </id_info>
  <brief_title>Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Seizure</brief_title>
  <official_title>Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Seizure: A Randomized, add-on Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, Bhubaneswar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, Bhubaneswar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epilepsy is one of the most common and frequently encountered neurological conditions that
      impose a huge burden on the healthcare systems. Despite the abundance of antiepileptic drugs
      (AEDs) available, 30% of people continue to have seizures even after long-term therapy of 6-8
      years. This group of people requires a more aggressive treatment since monotherapy, the first
      choice scheme, is not sufficient to control seizure and its complications, multiple drug
      therapy or polytherapy often results in the culmination of unwanted effects. The need for an
      add-on AEDs with a good safety profile is of utmost importance.The beneficial effects of
      melatonin on sleep, its wide safety window, and its ability to cross the blood-brain barrier
      have the potential to improve the quality of life in seizure patients. Various animal studies
      have suggested that melatonin receptors are the potential targets for anticonvulsant drug
      development. In animal studies, melatonin was found to suppress generalized seizure and
      seizure susceptibility and it also has neuroprotection and synapse modulating properties.
      Some clinical trials mostly on paediatric population also found that melatonin can improve
      the clinical outcome in epilepsy. Therefore, we have planned to conduct a randomized, add-on
      placebo-controlled clinical trial on the effect of melatonin on seizure outcome, neuronal
      damage and quality of life in adult patients with generalized seizure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epilepsy is a chronic disabling neurologic condition which often leads to numerous adverse
      long-term neurologic complications, such as behavioural and cognitive deficits, increased
      susceptibility to recurrent seizures, and neuronal injury or death. Cognitive dysfunction,
      depression, anxiety and sleep disorders are some of the highly prevalent and most
      debilitating complications of epilepsy. Despite the abundance of antiepileptic drugs (AEDs),
      even after long-term treatment of 6-8 years, 30% of patients continue having seizures. This
      group of patients requires a more aggressive treatment, since monotherapy fails to control
      seizures, considering the fact that the number of seizures is the single most important
      predictive factor for both early and long-term remission of seizures. Nevertheless,
      polytherapy often results in a number of adverse effects. The need for better-tolerated
      add-on therapy is the need of the hour to overcome this therapeutic hurdle.

      Melatonin, an endogenous hormone, acting through MT1 and MT2 receptors exert a depressive
      effect on brain excitability and have been shown to exert an anticonvulsant activity in
      various animal models. In some clinical trials also it has been found that add-on melatonin
      therapy improves the clinical outcome. Uberoset al evaluated the sleep-wake pattern, plasma
      melatonin levels and the urinary excretion of its metabolite among children with severe
      epileptic disorders, before and after a therapeutic trial with melatonin. They found sleep
      efficiency was significantly higher and better controls of convulsive episodes were achieved
      with among patients who received melatonin. Goldberg-Stern et aland Elkhayat et al concluded
      that melatonin could be effective and safe for decreasing seizure frequency and severity in
      patients with intractable epilepsy. Gupta et al found that melatonin has the potential to
      improve quality of life in pediatric epilepsy because of its beneficial effects on sleep, its
      wide safety window, and its ability to cross the blood-brain barrier. In another study by
      Jain SV et al melatonin resulted in a statistically significant decrease in sleep onset
      latency and wakefulness after sleep onset. Guptaet al also concluded that add-on melatonin
      can be of promise in the pharmacotherapy of pediatric epilepsy and as an adjunct, can be a
      putative neuroprotector in conditions involving oxidative stress like epilepsies. Dabak et al
      and Brazil et measured melatonin in febrile seizure and temporal lobe epilepsy and found to
      be lower in epilepsy in comparison to the controls.

      Our literature review reveals that till date most of the clinical studies on the effect of
      melatonin in epilepsy have been conducted in the pediatric population and there is no
      clinical trial done on its effect on seizure outcome, neuroprotective effect, sleep and
      circadian rhythm and quality of life in adult patients with epilepsy. So the present
      randomized clinical trial has been designed to fill the knowledge gap and evaluate the effect
      of add-on melatonin on seizure severity, neuronal damage and sleep quality in adult patients
      suffering from a generalized seizure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2018</start_date>
  <completion_date type="Actual">April 12, 2020</completion_date>
  <primary_completion_date type="Actual">March 3, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The recruited patients will be randomized by simple randomization into two treatment groups using computer-generated random codes. The random allocation code of the participants will be generated by PI who will not be involved in the patient recruitment. The codes will be assigned to a sequence of numbers and the numbered stickers will be pasted on the similar looking drug containers. The drug containers will be given to another investigator who will be responsible for patient recruitment. This process ensured allocation concealment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Responder Rate from baseline</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Responder rate is defined as percentage of patients having â‰¥50% reduction in seizure frequency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in seizure severity from baseline</measure>
    <time_frame>Baseline , 8 weeks</time_frame>
    <description>The change in seizure severity in terms of change in Chalfont-National Hospital seizure severity scale (NHS3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neuronal damage from baseline</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The change in neuronal damage in terms of change in serum NSE (Neuron-specific Enolase) level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep quality from the baseline</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The change in sleep quality in terms of change in Pittsburgh sleep quality index (PSQI) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in day time sleepiness from the baseline</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The change in daytime sleepiness in terms of change in Epworth sleepiness scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in antioxidant property from the baseline</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The change in antioxidant property in terms of change in serum glutathione reductase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the quality of life from the baseline</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The change in the quality of life in terms of change in Quality of Life in Epilepsy Inventory (QOLIE-31)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Generalized Seizure</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients in Control Arm will receive placebo with valproate (20 mg/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Experimental Arm will receive tablet melatonin as an add-on to valproate. Melatonin will be prescribed 3 mg/day to the patients and will be advised to take 30 minutes before bedtime.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 3 mg</intervention_name>
    <description>Melatonin 3 mg/ day with Valproate</description>
    <arm_group_label>Melatonin Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with Valproate</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with the clinical diagnosis of the generalized motor seizure (ILAE 2017)
             with a history of an episode of seizure within 72 hours of presentation.

          -  Patients aged 18-60 years, of either sex.

          -  Treatment-naive patients or patients who had not taken any treatment for at least 4
             weeks before inclusion.

        Exclusion Criteria:

          -  History of any recent traumatic brain injury, cerebral ischemia/TIA/stroke.

          -  Patients with neuroendocrinal tumors.

          -  History of any invasive neurosurgical/non-invasive neuropsychiatric procedure.

          -  Patients who are already under treatment for the presenting conditions.

          -  Medication history of psychoactive or central nervous system depressant drugs.

          -  Pregnant and nursing women.

          -  Patients with a history of allergy to valproate, melatonin or other melatonin
             agonists.

          -  Patients with drug/alcohol abuse.

          -  Patients with any hepatic dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debasish Hota, D.M</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, Bhubaneswar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences (AIIMS)</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia. 1998 Jan;39(1):81-8.</citation>
    <PMID>9578017</PMID>
  </reference>
  <results_reference>
    <citation>Vimala PV, Bhutada PS, Patel FR. Therapeutic potential of agomelatine in epilepsy and epileptic complications. Med Hypotheses. 2014 Jan;82(1):105-10. doi: 10.1016/j.mehy.2013.11.017. Epub 2013 Nov 21.</citation>
    <PMID>24314750</PMID>
  </results_reference>
  <results_reference>
    <citation>Cockerell OC, Sander JW, Shorvon SD. Remission of epilepsy. The NGPS. National General Practice Study of Epilepsy. Lancet. 1995 Nov 4;346(8984):1228.</citation>
    <PMID>7475682</PMID>
  </results_reference>
  <results_reference>
    <citation>MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JW, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol. 2000 Dec;48(6):833-41. Erratum in: Ann Neurol 2001 Apr;49(4):547. Ann Neurol 2001 Dec;50(6):830.</citation>
    <PMID>11117539</PMID>
  </results_reference>
  <results_reference>
    <citation>YalÃ½n O, Arman F, ErdoÄŸan F, Kula M. A comparison of the circadian rhythms and the levels of melatonin in patients with diurnal and nocturnal complex partial seizures. Epilepsy Behav. 2006 May;8(3):542-6. Epub 2006 Mar 9.</citation>
    <PMID>16524783</PMID>
  </results_reference>
  <results_reference>
    <citation>Costa-Lotufo LV, Fonteles MM, Lima IS, de Oliveira AA, Nascimento VS, de Bruin VM, Viana GS. Attenuating effects of melatonin on pilocarpine-induced seizures in rats. Comp Biochem Physiol C Toxicol Pharmacol. 2002 Apr;131(4):521-9.</citation>
    <PMID>11976067</PMID>
  </results_reference>
  <results_reference>
    <citation>Borowicz KK, KamiÅ„ski R, Gasior M, Kleinrok Z, Czuczwar SJ. Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. Eur Neuropsychopharmacol. 1999 Mar;9(3):185-90.</citation>
    <PMID>10208286</PMID>
  </results_reference>
  <results_reference>
    <citation>Lima E, Cabral FR, Cavalheiro EA, Naffah-Mazzacoratti Mda G, Amado D. Melatonin administration after pilocarpine-induced status epilepticus: a new way to prevent or attenuate postlesion epilepsy? Epilepsy Behav. 2011 Apr;20(4):607-12. doi: 10.1016/j.yebeh.2011.01.018. Epub 2011 Mar 30.</citation>
    <PMID>21454134</PMID>
  </results_reference>
  <results_reference>
    <citation>Yahyavi-Firouz-Abadi N, Tahsili-Fahadan P, Riazi K, Ghahremani MH, Dehpour AR. Involvement of nitric oxide pathway in the acute anticonvulsant effect of melatonin in mice. Epilepsy Res. 2006 Feb;68(2):103-13. Epub 2006 Jan 10.</citation>
    <PMID>16406488</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldberg-Stern H, Oren H, Peled N, Garty BZ. Effect of melatonin on seizure frequency in intractable epilepsy: a pilot study. J Child Neurol. 2012 Dec;27(12):1524-8. doi: 10.1177/0883073811435916. Epub 2012 Feb 28.</citation>
    <PMID>22378657</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta M, Aneja S, Kohli K. Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized, double-blind, placebo-controlled trial. Epilepsy Behav. 2004 Jun;5(3):316-21.</citation>
    <PMID>15145300</PMID>
  </results_reference>
  <results_reference>
    <citation>Singer MA. Effects of furosemide and ethacrynic acid on cation transport across phospholipid bilayer membranes. Can J Physiol Pharmacol. 1974 Oct;52(5):930-41.</citation>
    <PMID>4425994</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta M, Aneja S, Kohli K. Add-on melatonin improves sleep behavior in children with epilepsy: randomized, double-blind, placebo-controlled trial. J Child Neurol. 2005 Feb;20(2):112-5.</citation>
    <PMID>15794175</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta M, Gupta YK, Agarwal S, Aneja S, Kohli K. A randomized, double-blind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes. Br J Clin Pharmacol. 2004 Nov;58(5):542-7.</citation>
    <PMID>15521903</PMID>
  </results_reference>
  <results_reference>
    <citation>Bertaina-Anglade V, Drieu-La-Rochelle C, MocaÃ«r E, Seguin L. Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol Biochem Behav. 2011 Jun;98(4):511-7. doi: 10.1016/j.pbb.2011.02.015. Epub 2011 Feb 22.</citation>
    <PMID>21352847</PMID>
  </results_reference>
  <results_reference>
    <citation>Lopes MC, Quera-Salva MA, Guilleminault C. Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine). Sleep Med. 2007 Dec;9(1):33-41. Epub 2007 Sep 7.</citation>
    <PMID>17826314</PMID>
  </results_reference>
  <results_reference>
    <citation>AlAhmed S, Herbert J. Effect of agomelatine and its interaction with the daily corticosterone rhythm on progenitor cell proliferation in the dentate gyrus of the adult rat. Neuropharmacology. 2010 Nov;59(6):375-9. doi: 10.1016/j.neuropharm.2010.05.008. Epub 2010 Jun 1.</citation>
    <PMID>20685215</PMID>
  </results_reference>
  <results_reference>
    <citation>Bourin M, MocaÃ«r E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci. 2004 Mar;29(2):126-33.</citation>
    <PMID>15069466</PMID>
  </results_reference>
  <results_reference>
    <citation>Amudhan S, Gururaj G, Satishchandra P. Epilepsy in India I: Epidemiology and public health. Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):263-77. doi: 10.4103/0972-2327.160093. Review.</citation>
    <PMID>26425001</PMID>
  </results_reference>
  <results_reference>
    <citation>Fisher RS, Cross JH, D'Souza C, French JA, Haut SR, Higurashi N, Hirsch E, Jansen FE, Lagae L, MoshÃ© SL, Peltola J, Roulet Perez E, Scheffer IE, Schulze-Bonhage A, Somerville E, Sperling M, Yacubian EM, Zuberi SM. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017 Apr;58(4):531-542. doi: 10.1111/epi.13671. Epub 2017 Mar 8.</citation>
    <PMID>28276064</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol. 2016;56:361-83. doi: 10.1146/annurev-pharmtox-010814-124742. Epub 2015 Oct 23. Review.</citation>
    <PMID>26514204</PMID>
  </results_reference>
  <results_reference>
    <citation>Sanchez-Barcelo EJ, Rueda N, Mediavilla MD, Martinez-Cue C, Reiter RJ. Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders. Curr Med Chem. 2017 Nov 20;24(35):3851-3878. doi: 10.2174/0929867324666170718105557. Review.</citation>
    <PMID>28721826</PMID>
  </results_reference>
  <results_reference>
    <citation>Tchekalarova J, Petkova Z, Pechlivanova D, Moyanova S, Kortenska L, Mitreva R, Lozanov V, Atanasova D, Lazarov N, Stoynev A. Prophylactic treatment with melatonin after status epilepticus: effects on epileptogenesis, neuronal damage, and behavioral changes in a kainate model of temporal lobe epilepsy. Epilepsy Behav. 2013 Apr;27(1):174-87. doi: 10.1016/j.yebeh.2013.01.009. Epub 2013 Feb 28.</citation>
    <PMID>23435277</PMID>
  </results_reference>
  <results_reference>
    <citation>Mevissen M, Ebert U. Anticonvulsant effects of melatonin in amygdala-kindled rats. Neurosci Lett. 1998 Nov 20;257(1):13-6.</citation>
    <PMID>9857954</PMID>
  </results_reference>
  <results_reference>
    <citation>Rocha AKAA, de Lima E, Amaral F, Peres R, Cipolla-Neto J, Amado D. Altered MT1 and MT2 melatonin receptors expression in the hippocampus of pilocarpine-induced epileptic rats. Epilepsy Behav. 2017 Jun;71(Pt A):23-34. doi: 10.1016/j.yebeh.2017.01.020. Epub 2017 Apr 28.</citation>
    <PMID>28460319</PMID>
  </results_reference>
  <results_reference>
    <citation>Ma Y, Sun X, Li J, Jia R, Yuan F, Wei D, Jiang W. Melatonin Alleviates the Epilepsy-Associated Impairments in Hippocampal LTP and Spatial Learning Through Rescue of Surface GluR2 Expression at Hippocampal CA1 Synapses. Neurochem Res. 2017 May;42(5):1438-1448. doi: 10.1007/s11064-017-2200-5. Epub 2017 Feb 18.</citation>
    <PMID>28214985</PMID>
  </results_reference>
  <results_reference>
    <citation>Fenoglio-Simeone K, Mazarati A, Sefidvash-Hockley S, Shin D, Wilke J, Milligan H, Sankar R, Rho JM, Maganti R. Anticonvulsant effects of the selective melatonin receptor agonist ramelteon. Epilepsy Behav. 2009 Sep;16(1):52-7. doi: 10.1016/j.yebeh.2009.07.022. Epub 2009 Aug 13.</citation>
    <PMID>19682955</PMID>
  </results_reference>
  <results_reference>
    <citation>Brigo F, Igwe SC, Del Felice A. Melatonin as add-on treatment for epilepsy. Cochrane Database Syst Rev. 2016 Aug 11;(8):CD006967. doi: 10.1002/14651858.CD006967.pub4. Review.</citation>
    <PMID>27513702</PMID>
  </results_reference>
  <results_reference>
    <citation>Aguiar CC, Almeida AB, AraÃºjo PV, Vasconcelos GS, Chaves EM, do Vale OC, MacÃªdo DS, de Sousa FC, Viana GS, Vasconcelos SM. Anticonvulsant effects of agomelatine in mice. Epilepsy Behav. 2012 Jul;24(3):324-8. doi: 10.1016/j.yebeh.2012.04.134. Epub 2012 Jun 2.</citation>
    <PMID>22658946</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Donoghue MF, Duncan JS, Sander JW. The National Hospital Seizure Severity Scale: a further development of the Chalfont Seizure Severity Scale. Epilepsia. 1996 Jun;37(6):563-71.</citation>
    <PMID>8641234</PMID>
  </results_reference>
  <results_reference>
    <citation>Buysse DJ, Reynolds CF 3rd, Monk TH, Hoch CC, Yeager AL, Kupfer DJ. Quantification of subjective sleep quality in healthy elderly men and women using the Pittsburgh Sleep Quality Index (PSQI). Sleep. 1991 Aug;14(4):331-8. Erratum in: Sleep 1992 Feb;15(1):83.</citation>
    <PMID>1947597</PMID>
  </results_reference>
  <results_reference>
    <citation>Lerche H, Daniluk J, Lotay N, DeRossett S, Edwards S, Brandt C. Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. Seizure. 2015 Aug;30:93-100. doi: 10.1016/j.seizure.2015.06.002. Epub 2015 Jun 8.</citation>
    <PMID>26216692</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, Bhubaneswar</investigator_affiliation>
    <investigator_full_name>RITUPARNA MAITI</investigator_full_name>
    <investigator_title>Additional professor</investigator_title>
  </responsible_party>
  <keyword>Melatonin</keyword>
  <keyword>Neuron-specific Enolase</keyword>
  <keyword>Responder rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

